About Us

Avivagen is developing and commercializing products that promote health in animals and humans. The Corporation’s unique OxC-beta™ technology is a proprietary, first-in-class source of β-carotene-oxygen copolymer compounds that confer a variety of non-vitamin A health benefits. These benefits have wide, global utility, including replacement of antibiotics in livestock feeds, as well as for food-production conditions where antibiotics cannot be used, and supporting good health in companion animals.

Our Mission

Our mission is to deliver quality products to our customers by adopting best practices and continually monitoring industry trends to match and exceed the future expectations of the markets.

Our Goal

Avivagen Inc. operates in the multi-billion dollar animal and human health markets. The company’s goal is to commercialize a range of product applications from its technology platform with:

Secured licensing agreements

Collaborations and alliances with selected industry partners

The successful launch of pet products in the US, Canada and internationally

The strengthening of an already sound IP portfolio

Avivagen’s technology supports the natural systems that exist within the body to maintain optimal health and function, particularly by supporting immune function. Avivagen’s OxC-beta™ technology is based on its β-carotene-oxygen copolymer discovery.

Avivagen’s target markets are

Livestock Health & Productivity Enhancement

Pet Wellness

Human Health and Wellness

The OxC-beta™ platform addresses all three target markets.

Avivagen is a publicly listed biotechnology company trading on the TSX Venture Exchange under the ticker “VIV” and the OTC Pink Market under the ticker “CHEXF”. The company has two R&D operations located in the Industrial Partnership Facilities at the National Research Council of Canada (NRC) in Ottawa (Chemistry), and in Charlottetown, Prince Edward Island (Nutriscience). Avivagen is headquartered in Ottawa, Canada and was established August 4th, 2005.

The Avivagen Team

Kym Anthony

Chairman & Interim CEO

Extensive experience in capital markets, agriculture and life sciences